Pad Chivukula Sells 12,000 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Pad Chivukula sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now directly owns 435,334 shares in the company, valued at approximately $9,037,533.84. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Arcturus Therapeutics Price Performance

NASDAQ ARCT opened at $20.63 on Thursday. Arcturus Therapeutics Holdings Inc. has a 12 month low of $17.52 and a 12 month high of $45.00. The company has a 50-day moving average of $21.06 and a 200-day moving average of $25.53. The company has a market cap of $555.61 million, a P/E ratio of -5.28 and a beta of 2.61.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.85) by $1.21. The company had revenue of $49.86 million for the quarter, compared to analyst estimates of $21.00 million. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. During the same quarter last year, the business earned ($1.98) EPS. As a group, equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.6 EPS for the current year.

Analyst Upgrades and Downgrades

ARCT has been the subject of a number of analyst reports. Leerink Partnrs raised Arcturus Therapeutics to a “strong-buy” rating in a report on Monday, August 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, September 9th. Leerink Partners initiated coverage on shares of Arcturus Therapeutics in a report on Monday, August 12th. They set an “outperform” rating and a $70.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Tuesday, October 1st. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of “Buy” and an average target price of $71.40.

Institutional Investors Weigh In On Arcturus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new position in shares of Arcturus Therapeutics in the 1st quarter valued at about $40,000. nVerses Capital LLC acquired a new position in Arcturus Therapeutics during the third quarter valued at approximately $42,000. Quest Partners LLC grew its stake in Arcturus Therapeutics by 3,283.5% during the second quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock worth $90,000 after buying an additional 3,579 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Arcturus Therapeutics in the second quarter worth $142,000. Finally, CANADA LIFE ASSURANCE Co raised its stake in shares of Arcturus Therapeutics by 10.5% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 428 shares during the period. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.